Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP3 | O60896 | 15/20 | 0.52 |
| ▸ | CALCR | P30988 | 15/20 | 0.52 |
| ▸ | NPY2R | P49146 | 4/20 | 0.48 |
| ▸ | NPY4R | P50391 | 4/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.48 |
| ▸ | NPY1R | P25929 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6176082 | 0.84 | RAMP3 (0.54) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL6176075 | 0.83 | RAMP3 (0.52) | RAMP3CALCR | |
| SCHEMBL30390834 | 0.81 | RAMP3 (0.63) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30847581 | 0.80 | RAMP3 (0.60) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30455559 | 0.79 | RAMP3 (0.61) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL22550671 | 0.79 | RAMP3 (0.53) | RAMP3CALCR | |
| SCHEMBL31315523 | 0.78 | RAMP3 (0.57) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30401682 | 0.77 | F2 (0.48) | RAMP3CALCR | |
| SCHEMBL30128547 | 0.77 | PLG (0.47) | — | |
| SCHEMBL30432612 | 0.76 | RAMP3 (0.56) | RAMP3CALCRNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101722-A1 | HIGH-AFFINITY ENGINEERED CHROMODOMAINS | AXOIYA INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20250034162-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-01-30 | — | — | US | disclosed |
| US-12162955-B2 | CBX8 chromdomain inhibitors and the uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2024-12-10 | — | — | US | disclosed |
| US-12145944-B2 | Imidazopyrimidines as EED inhibitors and the use thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-11-19 | — | — | US | disclosed |
| CN-118745185-A | Imidazopyrimidines as EED inhibitors and use thereof | 密歇根大学董事会 | 2024-10-08 | — | — | CN | disclosed |
| US-20240316051-A1 | A PHARMACEUTICAL COMBINATION AND USE THEREOF | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2024-09-26 | — | — | US | disclosed |
| CN-115212311-B | Pharmaceutical composition and application thereof | 苏州亚盛药业有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| CN-114127073-B | Imidazopyrimidines as EED inhibitors and use thereof | 密歇根大学董事会 | 2024-05-31 | — | — | CN | disclosed |
| US-11931363-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2024-03-19 | — | — | US | disclosed |
| US-20230272452-A1 | COMBINATORIAL SINGLE MOLECULE ANALYSIS OF CHROMATIN | THE GENERAL HOSPITAL CORPORATION | 2023-08-31 | — | — | US | disclosed |
| US-20230257421-A1 | CBX8 CHROMDOMAIN INHIBITORS AND THE USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-08-17 | — | — | US | disclosed |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11566046-B2 | CBX8 chromdomain inhibitors and the uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-11548897-B2 | Crystalline forms of a triazolopyrimidine compound | NOVARTIS AG (CH) | 2023-01-10 | — | — | US | disclosed |
| US-11479805-B2 | Combinatorial single molecule analysis of chromatin | THE GENERAL HOSPITAL CORPORATION (US) | 2022-10-25 | — | — | US | disclosed |
| CN-115212311-A | Pharmaceutical composition and application thereof | 苏州亚盛药业有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-20220227778-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-07-21 | — | — | US | disclosed |
| CN-114746414-A | Aza-quinoline compounds and uses thereof | 诺华公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-3999510-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | The Regents Of The University Of Michigan (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931363-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | RAMP3 3798/4885CALCR 4729/4885NPY2R 3612/4885 |
| US-20240316051-A1 | A PHARMACEUTICAL COMBINATION AND USE THEREOF | EED, EML4, KIT | RAMP3 4469/4885CALCR 3433/4885NPY2R 4134/4885 |
| US-12145944-B2 | Imidazopyrimidines as EED inhibitors and the use thereof | EED, EEF1D, EEF1A1 | RAMP3 4257/4885CALCR 3364/4885NPY2R 2744/4885 |
| US-20230257421-A1 | CBX8 CHROMDOMAIN INHIBITORS AND THE USES THEREOF | CBX8, CBX3, CBX2 | RAMP3 3302/4885CALCR 3668/4885NPY2R 3773/4885 |
| US-11566046-B2 | CBX8 chromdomain inhibitors and the uses thereof | CBX8, CBX3, CBX2 | RAMP3 3302/4885CALCR 3668/4885NPY2R 3773/4885 |
| US-20250034162-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | EED, EEF1D, EEF1A1 | RAMP3 4257/4885CALCR 3364/4885NPY2R 2744/4885 |
| US-11548897-B2 | Crystalline forms of a triazolopyrimidine compound | EZH2, EED, SUZ12 | RAMP3 4540/4885CALCR 4863/4885NPY2R 4727/4885 |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | RAMP3 3798/4885CALCR 4729/4885NPY2R 3612/4885 |
| US-20220227778-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | EED, EEF1D, EEF1A1 | RAMP3 4257/4885CALCR 3364/4885NPY2R 2744/4885 |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | RAMP3 3798/4885CALCR 4729/4885NPY2R 3612/4885 |
| US-12162955-B2 | CBX8 chromdomain inhibitors and the uses thereof | CBX8, CBX3, CBX2 | RAMP3 3302/4885CALCR 3668/4885NPY2R 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.